Arcus Biosciences Inc. (RCUS)
NYSE: RCUS
· Real-Time Price · USD
13.36
-0.01 (-0.07%)
At close: Oct 03, 2025, 3:59 PM
13.35
-0.07%
After-hours: Oct 03, 2025, 05:45 PM EDT
-0.07% (1D)
| Bid | 13.33 |
| Market Cap | 1.42B |
| Revenue (ttm) | 262M |
| Net Income (ttm) | -306M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -4.25 |
| Forward PE | -3.17 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 13.36 |
| Volume | 1,159,764 |
| Avg. Volume (20D) | 946,401.6 |
| Open | 13.40 |
| Previous Close | 13.37 |
| Day's Range | 13.23 - 13.58 |
| 52-Week Range | 6.50 - 18.98 |
| Beta | 0.77 |
| Ex-Dividend Date | n/a |
About RCUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RCUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsArcus Biosciences Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-1.35%
Arcus Biosciences shares are trading lower after t...
Unlock content with
Pro Subscription
7 months ago
-16.34%
Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.
1 month ago · businesswire.com
Arcus Biosciences to Participate in Three Upcoming Investor ConferencesHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
1 month ago · seekingalpha.com
Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 MonthsArcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...
1 month ago · fool.com
Arcus (RCUS) Q2 Revenue Jumps 310%Arcus (RCUS) Q2 Revenue Jumps 310%
